Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

360

Enrollment

INDUSTRY

Sponsor class

Stopped IA did not meet the prespecified primary endpoint.

Conditions

IgA Nephropathy

Interventions

BIOLOGICAL: OMS721
OTHER: Vehicle (D5W or saline)

Sponsor

Omeros Corporation